Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 0.64 |
| ▸ | HTR1A | P08908 | 5/20 | 0.61 |
| ▸ | DRD3 | P35462 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.58 |
| ▸ | HRH1 | P35367 | 2/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4225899 | 0.98 | HTR7 (0.62) | HTR7HTR1ADRD3DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4224319 | 0.98 | HTR7 (0.62) | HTR7HTR1ADRD3DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4222983 | 0.98 | HTR7 (0.62) | HTR7HTR1ADRD3DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4231322 | 0.97 | HTR7 (0.61) | HTR7HTR1ADRD3DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4224101 | 0.97 | HTR7 (0.61) | HTR7HTR1ADRD3DRD2HTR2A | |
| SCHEMBL2795026 | 0.95 | HTR7 (0.63) | HTR7HTR1ADRD3DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4255618 | 0.93 | HTR7 (0.61) | HTR7HTR1ADRD3DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL31687556 | 0.93 | HTR7 (0.61) | HTR7HTR1ADRD3DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL7982174 | 0.93 | HTR7 (0.61) | HTR7HTR1ADRD3DRD2HTR2A | |
| Oxalic Acid SCHEMBL4228878 | 0.90 | HTR7 (0.65) | HTR7HTR1ADRD3DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014100730-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100719-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8188115-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-05-29 | — | — | US | disclosed |
| US-8188115-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-05-29 | — | — | US | disclosed |
| US-8188115-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-05-29 | — | — | US | disclosed |
| US-20090163542-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-20090163542-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-20090163542-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-7211585-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
| US-7211585-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
| US-20060040978-A1 | 5-HT7 receptor antagonists | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2006-02-23 | — | — | US | disclosed |
| EP-0922035-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2001-02-07 | — | — | EP | disclosed |
| US-6143762-A | DRUGS AS DOPAMINE ANTAGONIST PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM, PLC (GB) | 2000-11-07 | — | — | US | disclosed |
| EP-0922035-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998006699-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163542-A1 | 5-ht7 receptor antagonists | HTR7, HTR1A, HTR5A | HTR7 1/4885HTR1A 2/4885DRD3 122/4885 |
| US-20060040978-A1 | 5-HT7 receptor antagonists | HTR7, HTR1A, HTR5A | HTR7 1/4885HTR1A 2/4885DRD3 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.